## **Roland E Schmieder**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8309246/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 2018, 39, 3021-3104.	2.2	6,826
2	2007 Guidelines for the Management of Arterial Hypertension. Journal of Hypertension, 2007, 25, 1105-1187.	0.5	4,778
3	2013 ESH/ESC Guidelines for the management of arterial hypertension. Journal of Hypertension, 2013, 31, 1281-1357.	0.5	4,251
4	2018 ESC/ESH Guidelines for the management of arterial hypertension. Journal of Hypertension, 2018, 36, 1953-2041.	0.5	2,129
5	Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2) Tj ETQq1	1.0,7843 13.7	14 rgBT /0v 2,002
6	Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET) Tj ETQq0 0 0 rg	gBT /Overlo	ock 10 Tf 50 1,442
7	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Journal of Hypertension, 2009, 27, 2121-2158.	0.5	1,236
8	2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension. Journal of Hypertension, 2007, 25, 1751-1762.	0.5	1,152
9	2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). Journal of Hypertension, 2013, 31, 1925-1938.	0.5	789
10	A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. American Journal of Medicine, 2003, 115, 41-46.	1.5	686
11	Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet, The, 2017, 390, 2160-2170.	13.7	597
12	Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet, The, 2018, 391, 2346-2355.	13.7	597
13	Renin-angiotensin system and cardiovascular risk. Lancet, The, 2007, 369, 1208-1219.	13.7	583
14	2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Pressure, 2014, 23, 3-16.	1.5	565
15	Preeclampsia — A State of Sympathetic Overactivity. New England Journal of Medicine, 1996, 335, 1480-1485.	27.0	526
16	Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet, The, 2018, 391, 2335-2345.	13.7	526
17	Aliskiren, a Novel Orally Effective Renin Inhibitor, Provides Dose-Dependent Antihypertensive Efficacy and Placebo-Like Tolerability in Hypertensive Patients. Circulation, 2005, 111, 1012-1018.	1.6	485
18	Urinary Sodium and Potassium Excretion and Risk of Cardiovascular Events. JAMA - Journal of the American Medical Association, 2011, 306, 2229-38.	7.4	471

#	Article	IF	CITATIONS
19	Renal Sympathetic Denervation for Treatment of Drug-Resistant Hypertension. Circulation, 2012, 126, 2976-2982.	1.6	420
20	Prevention of Atrial Fibrillation by Renin-Angiotensin System Inhibition. Journal of the American College of Cardiology, 2010, 55, 2299-2307.	2.8	374
21	2013 ESH/ESC Guidelines for the management of arterial hypertension. Blood Pressure, 2013, 22, 193-278.	1.5	355
22	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Pressure, 2009, 18, 308-347.	1.5	351
23	Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL) Tj ETQq1 1444-1451.	l 0.78431 13.7	4 rgBT /Over 351
24	<sup>23</sup> Na Magnetic Resonance Imaging-Determined Tissue Sodium in Healthy Subjects and Hypertensive Patients. Hypertension, 2013, 61, 635-640.	2.7	332
25	Renal Hemodynamics and Renal Function After Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension. Hypertension, 2012, 60, 419-424.	2.7	289
26	Dietary salt intake. A determinant of cardiac involvement in essential hypertension Circulation, 1988, 78, 951-956.	1.6	271
27	Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARCET and TRANSCEND trials. Lancet, The, 2017, 389, 2226-2237.	13.7	263
28	Ambulatory Blood Pressure Changes After Renal Sympathetic Denervation in Patients With Resistant Hypertension. Circulation, 2013, 128, 132-140.	1.6	240
29	Increased Bioavailability of Nitric Oxide After Lipid-Lowering Therapy in Hypercholesterolemic Patients. Circulation, 1998, 98, 211-216.	1.6	234
30	Changes in Albuminuria Predict Mortality and Morbidity in Patients with Vascular Disease. Journal of the American Society of Nephrology: JASN, 2011, 22, 1353-1364.	6.1	234
31	New Approaches in the Treatment of Hypertension. Circulation Research, 2015, 116, 1074-1095.	4.5	233
32	ESH Position Paper. Journal of Hypertension, 2012, 30, 837-841.	0.5	227
33	Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. European Heart Journal, 2014, 35, 1752-1759.	2.2	227
34	<sup>23</sup> Na Magnetic Resonance Imaging of Tissue Sodium. Hypertension, 2012, 59, 167-172.	2.7	223
35	Left Ventricular Hypertrophy and Clinical Outcomes in Hypertensive Patients. American Journal of Hypertension, 2008, 21, 500-508.	2.0	206

 $_{36}$  Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 rgBT

#	Article	IF	CITATIONS
37	Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. Journal of Hypertension, 2008, 26, 403-411.	0.5	190
38	Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. European Heart Journal, 2019, 40, 3474-3482.	2.2	189
39	Accuracy of Cuff-Measured Blood Pressure. Journal of the American College of Cardiology, 2017, 70, 572-586.	2.8	186
40	The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure – a prospective, randomized, controlled prevention trial of the German Hypertension League. Journal of Hypertension, 2008, 26, 1487-1496.	0.5	182
41	Hypertension and atrial fibrillation. Journal of Hypertension, 2012, 30, 239-252.	0.5	177
42	First Report of the Global SYMPLICITY Registry on the Effect of Renal Artery Denervation in Patients With Uncontrolled Hypertension. Hypertension, 2015, 65, 766-774.	2.7	172
43	Meta-analysis. Update on reversal of left ventricular hypertrophy in essential hypertension (a) Tj ETQq1 1 0.7843 Transplantation, 1998, 13, 564-569.	814 rgBT /( 0.7	Overlock 10 T 168
44	Effect of Telmisartan on Renal Outcomes. Annals of Internal Medicine, 2009, 151, 1.	3.9	163
45	Skin Sodium Concentration Correlates with Left Ventricular Hypertrophy in CKD. Journal of the American Society of Nephrology: JASN, 2017, 28, 1867-1876.	6.1	157
46	Blood Pressure Targets Recommended by Guidelines and Incidence of Cardiovascular and Renal Events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation, 2011, 124, 1727-1736.	1.6	156
47	Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial. Lancet, The, 2015, 385, 1634-1641.	13.7	155
48	Salt and Hypertension: Is Salt Dietary Reduction Worth the Effort?. American Journal of Medicine, 2012, 125, 433-439.	1.5	154
49	SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial. Cardiovascular Diabetology, 2018, 17, 5.	6.8	147
50	Additional Antiproteinuric Effect of Ultrahigh Dose Candesartan. Journal of the American Society of Nephrology: JASN, 2005, 16, 3038-3045.	6.1	146
51	Impaired Endothelial Function of the Retinal Vasculature in Hypertensive Patients. Stroke, 2004, 35, 1289-1293.	2.0	145
52	Impaired endothelial function in arterial hypertension and hypercholesterolemia. Journal of Hypertension, 2000, 18, 363-374.	0.5	142
53	Increased Wall:Lumen Ratio of Retinal Arterioles in Male Patients With a History of a Cerebrovascular Event. Hypertension, 2007, 50, 623-629.	2.7	139
54	Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension, Journal of Hypertension, 2012, 30, 1047-1055.	0.5	134

#	Article	IF	CITATIONS
55	Long-Term Antihypertensive Efficacy and Safety of the Oral Direct Renin Inhibitor Aliskiren. Circulation, 2009, 119, 417-425.	1.6	129
56	Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. American Heart Journal, 2005, 149, 473.e1-473.e10.	2.7	127
57	International Expert Consensus Statement. Journal of the American College of Cardiology, 2013, 62, 2031-2045.	2.8	124
58	Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. International Journal of Cardiology, 2013, 168, 2214-2220.	1.7	122
59	Angiotensin II Related to Sodium Excretion Modulates Left Ventricular Structure in Human Essential Hypertension. Circulation, 1996, 94, 1304-1309.	1.6	120
60	Impact of Telmisartan Versus Ramipril on Renal Endothelial Function in Patients With Hypertension and Type 2 Diabetes. Diabetes Care, 2007, 30, 1351-1356.	8.6	119
61	Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus. Circulation, 2017, 136, 1167-1169.	1.6	119
62	A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation. Cardiovascular Diabetology, 2017, 16, 26.	6.8	115
63	Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL) Tj ETQq1	1 0.78431 13.7	4 rgBT /Over
64	Rapid Nongenomic Effects of Aldosterone on Human Forearm Vasculature. Hypertension, 2003, 42, 156-160.	2.7	113
65	Beyond salt: lifestyle modifications and blood pressure. European Heart Journal, 2011, 32, 3081-3087.	2.2	111
66	Reduced Effect of Percutaneous Renal Denervation on Blood Pressure in Patients With Isolated Systolic Hypertension. Hypertension, 2015, 65, 193-199.	2.7	109
67	Renal denervation preserves renal function in patients with chronic kidney disease and resistant hypertension. Journal of Hypertension, 2015, 33, 1261-1266.	0.5	103
68	End Organ Damage In Hypertension. Deutsches Ärzteblatt International, 2010, 107, 866-73.	0.9	102
69	Low-grade albuminuria and cardiovascular risk. Clinical Research in Cardiology, 2007, 96, 247-257.	3.3	99
70	Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control After Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. Circulation, 2019, 139, 2542-2553.	1.6	97
71	Renal Denervation in Moderate Treatment-Resistant Hypertension. Journal of the American College of Cardiology, 2013, 62, 1880-1886.	2.8	93
72	Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120–140) Tj ETQq0 0 (	) rgBT /Ove	erlock 10 Tf 5 92

trials. European Heart Journal, 2018, 39, 3105-3114.

#	Article	IF	CITATIONS
73	Analysis of retinal arteriolar structure in never-treated patients with essential hypertension. Journal of Hypertension, 2008, 26, 1427-1434.	0.5	90
74	European Society of Hypertension position paper on renal denervation 2021. Journal of Hypertension, 2021, 39, 1733-1741.	0.5	88
75	Effect of the angiotensin II type 2-receptor gene (+1675 G/A) on left ventricular structure in humans. Journal of the American College of Cardiology, 2001, 37, 175-182.	2.8	84
76	Hypertension and the heart. Journal of Human Hypertension, 2000, 14, 597-604.	2.2	82
77	How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial. Cardiovascular Diabetology, 2019, 18, 44.	6.8	80
78	Renal Denervation in High-Risk Patients With Hypertension. Journal of the American College of Cardiology, 2020, 75, 2879-2888.	2.8	80
79	Assessment of endothelial function of the renal vasculature in human subjects. American Journal of Hypertension, 2002, 15, 3-9.	2.0	75
80	Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice, 2007, 61, 1461-1468.	1.7	75
81	Renal Denervation Update From theÂInternational Sympathetic NervousÂSystem Summit. Journal of the American College of Cardiology, 2019, 73, 3006-3017.	2.8	74
82	Glomerular hyperfiltration during sympathetic nervous system activation in early essential hypertension Journal of the American Society of Nephrology: JASN, 1997, 8, 893-900.	6.1	74
83	Alcohol-Mediated Renal Denervation Using the Peregrine System Infusion Catheter for Treatment of Hypertension. JACC: Cardiovascular Interventions, 2020, 13, 471-484.	2.9	73
84	Measurement of kidney perfusion by magnetic resonance imaging: comparison of MRI with arterial spin labeling to para-aminohippuric acid plasma clearance in male subjects with metabolic syndrome. Nephrology Dialysis Transplantation, 2010, 25, 1126-1133.	0.7	70
85	The role of non-haemodynamic factors of the genesis of LVH. Nephrology Dialysis Transplantation, 2005, 20, 2610-2612.	0.7	69
86	Improvement of albuminuria after renal denervation. International Journal of Cardiology, 2014, 173, 311-315.	1.7	69
87	Central Pulse Pressure Is an Independent Determinant of Vascular Remodeling in the Retinal Circulation. Hypertension, 2013, 61, 1340-1345.	2.7	68
88	New developments in the pathogenesis of obesity-induced hypertension. Journal of Hypertension, 2015, 33, 1499-1508.	0.5	68
89	Does obesity influence early target organ damage in hypertensive patients?. Circulation, 1993, 87, 1482-1488.	1.6	67
90	Wall-to-Lumen Ratio of Retinal Arterioles and Arteriole-to-Venule Ratio of Retinal Vessels in Patients with Cerebrovascular Damage. , 2009, 50, 4351.		67

#	Article	IF	CITATIONS
91	Cardiac performance after reduction of myocardial hypertrophy. American Journal of Medicine, 1989, 87, 22-27.	1.5	65
92	Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient. Journal of Hypertension, 2014, 32, 1888-1897.	0.5	65
93	A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs. American Heart Journal, 2018, 195, 115-129.	2.7	64
94	Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation. Journal of the American College of Cardiology, 2021, 77, 2909-2919.	2.8	63
95	Wall-to-Lumen Ratio of Retinal Arterioles as a Tool to Assess Vascular Changes. Hypertension, 2009, 54, 384-387.	2.7	61
96	Renal Denervation for TreatingÂHypertension. JACC: Cardiovascular Interventions, 2019, 12, 1095-1105.	2.9	61
97	Updated ESH position paper on interventional therapy of resistant hypertension. EuroIntervention, 2013, 9, R58-R66.	3.2	60
98	Left ventricular hypertrophy and its regression: pathophysiology and therapeutic approachFocus on treatment by antihypertensive agents. American Journal of Hypertension, 1998, 11, 1394-1404.	2.0	59
99	New software analyses increase the reliability of measurements of retinal arterioles morphology by scanning laser Doppler flowmetry in humans. Journal of Hypertension, 2011, 29, 777-782.	0.5	59
100	Non-invasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients. European Heart Journal Cardiovascular Imaging, 2017, 18, 945-960.	1.2	59
101	Remodeling of Retinal Small Arteries in Hypertension. American Journal of Hypertension, 2011, 24, 1267-1273.	2.0	56
102	Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes. Cardiovascular Diabetology, 2014, 13, 19.	6.8	56
103	Rationale and design of a large registry on renal denervation: the Global SYMPLICITY registry. EuroIntervention, 2013, 9, 484-492.	3.2	56
104	Wilder's principle: pre-treatment value determines post-treatment response. European Heart Journal, 2015, 36, 576-579.	2.2	55
105	Medication adherence in hypertension. Journal of Hypertension, 2020, 38, 579-587.	0.5	55
106	Accelerated decline in renal perfusion with aging in essential hypertension Hypertension, 1994, 23, 351-357.	2.7	54
107	Analysis of NO-synthase expression and clinical risk factors in human diabetic nephropathy. Nephrology Dialysis Transplantation, 2007, 23, 1346-1354.	0.7	54
108	Adherence to Antihypertensive Medication in Treatmentâ€Resistant Hypertension Undergoing Renal Denervation. Journal of the American Heart Association, 2016, 5, .	3.7	54

#	Article	IF	CITATIONS
109	Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. Journal of Hypertension, 2009, 27, 673-679.	0.5	53
110	Why in 2016 are patients with hypertension not 100% controlled? A call to action. Journal of Hypertension, 2016, 34, 1480-1488.	0.5	52
111	Salt. A perpetrator of hypertensive target organ disease?. Archives of Internal Medicine, 1997, 157, 2449-2452.	3.8	52
112	Vascular and Renal Hemodynamic Changes after Renal Denervation. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1195-1201.	4.5	51
113	Obesity as a determinant for response to antihypertensive treatment BMJ: British Medical Journal, 1993, 307, 537-540.	2.3	47
114	Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk. European Heart Journal, 2019, 40, 2032-2043.	2.2	47
115	Patient preference for therapies in hypertension: a cross-sectional survey of German patients. Clinical Research in Cardiology, 2019, 108, 1331-1342.	3.3	47
116	12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation. JACC: Cardiovascular Interventions, 2020, 13, 2922-2933.	2.9	47
117	The role of nitric oxide in the regulation of glomerular haemodynamics in humans. Nephrology Dialysis Transplantation, 2004, 19, 1392-1397.	0.7	46
118	What the interventionalist should know about renal denervation in hypertensive patients: a position paper by the ESH WG on the interventional treatment of hypertension. EuroIntervention, 2014, 9, 1027-1035.	3.2	46
119	Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension11See Editorial by Noris and Remuzzi, p. 1545 Kidney International, 2002, 61, 1462-1468.	5.2	45
120	Renal resistive index in addition to low-grade albuminuria complements screening for target organ damage in therapy-resistant hypertension. Journal of Hypertension, 2010, 28, 608-614.	0.5	45
121	Central pulse pressure predicts BP reduction after renal denervation in patients with treatment-resistant hypertension. EuroIntervention, 2015, 11, 110-116.	3.2	45
122	Central Iliac Arteriovenous Anastomosis for Uncontrolled Hypertension. Hypertension, 2017, 70, 1099-1105.	2.7	44
123	Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial. Journal of Hypertension, 2009, 27, 1493-1501.	0.5	43
124	Wall-to-lumen ratio of retinal arterioles is related with urinary albumin excretion and altered vascular reactivity to infusion of the nitric oxide synthase inhibitor N-monomethyl-L-arginine. Journal of Hypertension, 2009, 27, 2201-2208.	0.5	42
125	Effects of renal sympathetic denervation on urinary sodium excretion in patients with resistant hypertension. Clinical Research in Cardiology, 2015, 104, 672-678.	3.3	42
126	Diagnosis and treatment of arterial hypertension 2021. Kidney International, 2022, 101, 36-46.	5.2	41

#	Article	IF	CITATIONS
127	Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies. Diabetologia, 2014, 57, 2019-2029.	6.3	40
128	Phase II randomized sham-controlled study of renal denervation for individuals with uncontrolled hypertension – WAVE IV. Journal of Hypertension, 2018, 36, 680-689.	0.5	40
129	Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline. Journal of Hypertension, 2014, 32, 1741-1750.	0.5	39
130	European Society of Hypertension position paper on renal denervation 2018. Journal of Hypertension, 2018, 36, 2042-2048.	0.5	39
131	Tonic Postganglionic Sympathetic Inhibition Induced by Afferent Renal Nerves?. Hypertension, 2012, 59, 467-476.	2.7	38
132	Renal Vascular Endothelial Function in Hypertensive Patients With Type 2 Diabetes Mellitus. American Journal of Kidney Diseases, 2009, 53, 281-289.	1.9	37
133	Improvement of hypertension management by structured physician education and feedback system: cluster randomized trial. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 271-279.	2.8	37
134	Physician attitudes to blood pressure control. Journal of Hypertension, 2011, 29, 1633-1640.	0.5	37
135	Disproportional Decrease in Office Blood Pressure Compared With 24-Hour Ambulatory Blood Pressure With Antihypertensive Treatment. Hypertension, 2014, 64, 1067-1072.	2.7	37
136	Renal Denervation in a Hypertensive Patient With Endâ€Stage Renal Disease and Small Arteries: A Direction for Future Research. Journal of Clinical Hypertension, 2012, 14, 799-801.	2.0	35
137	Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials. European Heart Journal, 2020, 41, 231-238.	2.2	35
138	Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertension. American Journal of Hypertension, 2003, 16, 1030-1035.	2.0	34
139	Increased response of renal perfusion to the antioxidant vitamin C in type 2 diabetes. Nephrology Dialysis Transplantation, 2004, 19, 2513-2518.	0.7	34
140	Blood Pressure Control in Patients With Comorbidities. Journal of Clinical Hypertension, 2008, 10, 624-631.	2.0	34
141	Rationale, Design, and Baseline Characteristics of ARTS-DN: A Randomized Study to Assess the Safety and Efficacy of Finerenone in Patients with Type 2 Diabetes Mellitus and a Clinical Diagnosis of Diabetic Nephropathy. American Journal of Nephrology, 2014, 40, 572-581.	3.1	33
142	Retinal capillary rarefaction in patients with untreated mild-moderate hypertension. BMC Cardiovascular Disorders, 2017, 17, 300.	1.7	33
143	MASked-unconTrolled hypERtension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol. BMJ Open, 2018, 8, e021038.	1.9	33
144	Confounding Factors in Renal Denervation Trials. Hypertension, 2020, 76, 1410-1417.	2.7	33

#	Article	IF	CITATIONS
145	Impact of dietary sodium intake on left ventricular diastolic filling in early essential hypertension. European Heart Journal, 1998, 19, 951-958.	2.2	32
146	Relative and Combined Prognostic Importance of On-Treatment Mean and Visit-to-Visit Blood Pressure Variability in ONTARGET and TRANSCEND Patients. Hypertension, 2017, 70, 938-948.	2.7	31
147	Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. Nephrology Dialysis Transplantation, 2023, 38, 10-25.	0.7	30
148	Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure. Cardiovascular Diabetology, 2021, 20, 219.	6.8	30
149	Is l-arginine infusion an adequate tool to assess endothelium-dependent vasodilation of the human renal vasculature?. Clinical Science, 2000, 99, 293-302.	4.3	29
150	Externally Delivered Focused UltrasoundÂfor Renal Denervation. JACC: Cardiovascular Interventions, 2016, 9, 1292-1299.	2.9	29
151	Blood Pressure Pattern and Target Organ Damage in Patients With Chronic Kidney Disease. Hypertension, 2018, 72, 929-936.	2.7	29
152	Differences in patient and physician perspectives on pharmaceutical therapy and renal denervation for the management of hypertension. Journal of Hypertension, 2021, 39, 162-168.	0.5	29
153	Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia. Atherosclerosis, 2008, 196, 704-711.	0.8	28
154	Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design, Clinical Research in Cardiology, 2020, 109, 289-302.	3.3	28
155	Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium. Circulation, 2022, 145, 847-863.	1.6	28
156	Impaired Sodium Excretion During Mental Stress in Mild Essential Hypertension. Hypertension, 2001, 37, 923-927.	2.7	27
157	Local application of tropicamide 0.5% reduces retinal capillary blood flow. Blood Pressure, 2013, 22, 371-376.	1.5	27
158	Influence of Age on Upper Arm Cuff Blood Pressure Measurement. Hypertension, 2020, 75, 844-850.	2.7	27
159	Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension. Journal of the American College of Cardiology, 2021, 78, 1028-1038.	2.8	27
160	Stress response pattern in obesity and systemic hypertension. American Journal of Cardiology, 1992, 70, 1035-1039.	1.6	26
161	Renal denervation—implications for chronic kidney disease. Nature Reviews Nephrology, 2014, 10, 305-313.	9.6	26
162	Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT. Journal of Hypertension, 2016, 34, 393-396.	0.5	26

#	Article	IF	CITATIONS
163	Cocoa Flavanol Cardiovascular Effects Beyond Blood Pressure Reduction. Journal of Clinical Hypertension, 2016, 18, 352-358.	2.0	26
164	Effects of manidipine <i>vs.</i> amlodipine on intrarenal haemodynamics in patients with arterial hypertension. British Journal of Clinical Pharmacology, 2013, 75, 129-135.	2.4	25
165	Angiotensin II stimulates left ventricular hypertrophy in hypertensive patients independently of blood pressure. American Journal of Hypertension, 1999, 12, 418-422.	2.0	24
166	Impaired basal NO activity in patients with glomerular disease and the influence of oxidative stress. Kidney International, 2006, 70, 1177-1181.	5.2	24
167	Basal nitric oxide synthase activity is a major determinant of glomerular haemodynamics in humans. Journal of Hypertension, 2008, 26, 110-116.	0.5	24
168	Reduction in Basal Nitric Oxide Activity Causes Albuminuria. Diabetes, 2011, 60, 572-576.	0.6	24
169	Impaired Increase of Retinal Capillary Blood Flow to Flicker Light Exposure in Arterial Hypertension. Hypertension, 2012, 60, 871-876.	2.7	24
170	GuÃa de práctica clÃnica de la ESH/ESC para el manejo de la hipertensión arterial (2013). Revista Espanola De Cardiologia, 2013, 66, 880.e1-880.e64.	1.2	24
171	Low doseâ€eplerenone treatment decreases aortic stiffness in patients with resistant hypertension. Journal of Clinical Hypertension, 2017, 19, 669-676.	2.0	24
172	Tissue sodium content in patients with type 2 diabetes mellitus. Journal of Diabetes and Its Complications, 2019, 33, 485-489.	2.3	24
173	Plasma soluble adhesion molecules and endothelium-dependent vasodilation in early human atherosclerosis. Clinical Science, 2000, 98, 521-529.	4.3	23
174	Effect of Arteriovenous Anastomosis on Blood Pressure Reduction in Patients With Isolated Systolic Hypertension Compared With Combined Hypertension. Journal of the American Heart Association, 2016, 5, .	3.7	22
175	Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry. BMC Cardiovascular Disorders, 2016, 16, 56.	1.7	22
176	Renal denervation in patients with versus without chronic kidney disease: results from the Global SYMPLICITY Registry with follow-up data of 3 years. Nephrology Dialysis Transplantation, 2022, 37, 304-310.	0.7	22
177	Antihypertensive therapy. To stop or not to stop?. JAMA - Journal of the American Medical Association, 1991, 265, 1566-1571.	7.4	22
178	Retinal Capillary Rarefaction in Patients with Type 2 Diabetes Mellitus. PLoS ONE, 2016, 11, e0162608.	2.5	22
179	Validation of a therapeutic scheme for the treatment of resistant hypertension. Journal of the American Society of Hypertension, 2011, 5, 498-504.	2.3	21
180	Renal denervation in hypertensive patients not on blood pressure lowering drugs. Clinical Research in Cardiology, 2016, 105, 755-762.	3.3	21

#	Article	IF	CITATIONS
181	Impact of NO-synthase inhibition on renal hemodynamics in normotensive and hypertensive subjects. Journal of Hypertension, 2002, 20, 525-530.	0.5	20
182	Influence of blood flow on arteriolar wall-to-lumen ratio in the human retinal circulation in vivo. Microvascular Research, 2012, 83, 111-117.	2.5	20
183	Renal protection by low dose irbesartan in diabetic nephropathy is paralleled by a reduction of inflammation, not of endoplasmic reticulum stress. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 558-565.	3.8	20
184	Renal denervation: where do we stand and what is the relevance to the nephrologist?. Nephrology Dialysis Transplantation, 2022, 37, 638-644.	0.7	20
185	Renal protection with angiotensin receptor blockers: where do we stand. Journal of Nephrology, 2011, 24, 569-580.	2.0	20
186	L-Arginine-Induced Vasodilation of the Renal Vasculature Is Not Altered in Hypertensive Patients With Type 2 Diabetes. Diabetes Care, 2003, 26, 1836-1840.	8.6	19
187	Review of direct renin inhibition by aliskiren. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2013, 14, 193-196.	1.7	19
188	Clinical situations associated with difficult-to-control hypertension. Journal of Hypertension, 2013, 31, S3-S8.	0.5	19
189	A guide for easy- and difficult-to-treat hypertension. International Journal of Cardiology, 2014, 172, 17-22.	1.7	19
190	Renal denervation reduces office and ambulatory heart rate in patients with uncontrolled hypertension. Journal of Hypertension, 2016, 34, 2480-2486.	0.5	19
191	Reproducibility of Kidney Perfusion Measurements With Arterial Spin Labeling at 1.5 Tesla MRI Combined With Semiautomatic Segmentation for Differential Cortical and Medullary Assessment. Medicine (United States), 2016, 95, e3083.	1.0	19
192	Effects of linagliptin on renal endothelial function in patients with type 2 diabetes: a randomised clinical trial. Diabetologia, 2016, 59, 2579-2587.	6.3	19
193	Improvement in Retinal Capillary Rarefaction After Valsartan Treatment in Hypertensive Patients. Journal of Clinical Hypertension, 2016, 18, 1112-1118.	2.0	19
194	Retinal capillary and arteriolar changes in patients with chronic kidney disease. Microvascular Research, 2018, 118, 121-127.	2.5	19
195	Individualised treatment targets in patients with type-2 diabetes and hypertension. Cardiovascular Diabetology, 2018, 17, 18.	6.8	19
196	Interpreting treatment-induced blood pressure reductions measured by ambulatory blood pressure monitoring. Journal of Human Hypertension, 2013, 27, 715-720.	2.2	18
197	How should data from SYMPLICITY HTN-3 be interpreted?. Nature Reviews Cardiology, 2014, 11, 375-376.	13.7	18
198	Clinical Impact of Patient Adherence to a Fixed-Dose Combination of Olmesartan, Amlodipine and Hydrochlorothiazide. Clinical Drug Investigation, 2014, 34, 403-411.	2.2	18

#	Article	IF	CITATIONS
199	Renal denervation improves 24â€hour central and peripheral blood pressures, arterial stiffness, and peripheral resistance. Journal of Clinical Hypertension, 2018, 20, 366-372.	2.0	18
200	Improved cardiovascular risk prediction in patients with end-stage renal disease on hemodialysis using machine learning modeling and circulating microribonucleic acids. Theranostics, 2020, 10, 8665-8676.	10.0	18
201	Facing the Challenge of Lowering Blood Pressure and Cholesterol in the Same Patient: Report of a Symposium at the European Society of Hypertension. Cardiology and Therapy, 2020, 9, 19-34.	2.6	18
202	The role of statins in the treatment of the metabolic syndrome. Current Hypertension Reports, 2009, 11, 143-149.	3.5	17
203	Impact of renal denervation on tissue Na+ content in treatment-resistant hypertension. Clinical Research in Cardiology, 2018, 107, 42-48.	3.3	17
204	Changes in 24-Hour Patterns of Blood Pressure in Hypertension Following Renal Denervation Therapy. Hypertension, 2019, 74, 244-249.	2.7	17
205	Effect of renal denervation in attenuating the stress of morning surge in blood pressure: post-hoc analysis from the SPYRAL HTN-ON MED trial. Clinical Research in Cardiology, 2021, 110, 725-731.	3.3	17
206	Efficacy and safety of olmesartan medoxomil plus amlodipine in age, gender and hypertension severity defined subgroups of hypertensive patients. Journal of Human Hypertension, 2011, 25, 354-363.	2.2	16
207	Early vascular parameters in the micro- and macrocirculation in type 2 diabetes. Cardiovascular Diabetology, 2018, 17, 128.	6.8	16
208	Catheter-based alcohol-mediated renal denervation for the treatment of uncontrolled hypertension: design of two sham-controlled, randomized, blinded trials in the absence (TARGET BP OFF-MED) and presence (TARGET BP I) of antihypertensive medications. American Heart Journal, 2021, 239, 90-99.	2.7	16
209	Salt intake, blood pressure, and cardiovascular structure. Cardiovascular Drugs and Therapy, 1994, 8, 425-432.	2.6	15
210	Effects of folic acid on renal endothelial function in patients with diabetic nephropathy: results from a randomized trial. Clinical Science, 2014, 127, 499-505.	4.3	15
211	Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin. Clinical Research in Cardiology, 2015, 104, 621-631.	3.3	15
212	Diuretic therapy and the risk for renal cell carcinoma. Journal of Nephrology, 2000, 13, 343-6.	2.0	15
213	High sodium intake modulates left ventricular mass in patients with G expression of +1675 G/A angiotensin II receptor type 2 gene. Journal of Hypertension, 2007, 25, 1627-1632.	0.5	14
214	Basal nitric oxide activity is an independent determinant of arteriolar structure in the human retinal circulation. Journal of Hypertension, 2011, 29, 123-129.	0.5	14
215	Rosuvastatin improves pulse wave reflection by restoring endothelial function. Microvascular Research, 2012, 84, 60-64.	2.5	14
216	25-Hydroxyvitamin D insufficiency is associated with impaired renal endothelial function and both are improved with rosuvastatin treatment. Clinical Research in Cardiology, 2013, 102, 299-304.	3.3	14

#	Article	IF	CITATIONS
217	Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk. Journal of Hypertension, 2014, 32, 1334-1341.	O.5	14
218	Predictors of atherosclerotic events in patients on haemodialysis: post hoc analyses from the AURORA study. Nephrology Dialysis Transplantation, 2016, 33, gfw360.	0.7	14
219	Effects of renal denervation on blood pressure in hypertensive patients with end-stage renal disease: a single centre experience. Clinical and Experimental Nephrology, 2019, 23, 749-755.	1.6	14
220	Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study. Journal of Human Hypertension, 2022, 36, 629-639.	2.2	14
221	Effects of the sodiumâ€glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure. ESC Heart Failure, 2021, 8, 5327-5337.	3.1	14
222	Barriers to cardiovascular risk prevention and management in Germany – an analysis of the EURIKA study. Vascular Health and Risk Management, 2012, 8, 177.	2.3	13
223	Poor Glycemic Control Is Related to Increased Nitric Oxide Activity Within the Renal Circulation of Patients With Type 2 Diabetes. Diabetes Care, 2013, 36, 4071-4075.	8.6	13
224	Effect of aliskiren on vascular remodelling in small retinal circulation. Journal of Hypertension, 2015, 33, 2491-2499.	0.5	13
225	Retinal vascular resistance in arterial hypertension. Blood Pressure, 2018, 27, 82-87.	1.5	13
226	Attenuation of Splanchnic Autotransfusion Following Noninvasive Ultrasound Renal Denervation: A Novel Marker of Procedural Success. Journal of the American Heart Association, 2018, 7, .	3.7	13
227	Relation of the first hypertension-associated event with medication, compliance and persistence in naÃ <sup>-</sup> ve hypertensive patients after initiating monotherapy. International Journal of Clinical Pharmacology and Therapeutics, 2010, 48, 173-183.	0.6	13
228	Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice. Vascular Health and Risk Management, 2010, 6, 803.	2.3	12
229	Expertise. Journal of Hypertension, 2017, 35, 1564-1566.	O.5	12
230	Telmisartan in incipient and overt diabetic renal disease. Journal of Nephrology, 2011, 24, 263-273.	2.0	12
231	Reversibility of the Effects of Aliskiren in the Renal Versus Systemic Circulation. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 258-264.	4.5	11
232	Urinary Albumin Excretion From Spot Urine Samples Predict All-Cause and Stroke Mortality in Africans. American Journal of Hypertension, 2014, 27, 811-818.	2.0	11
233	First experience in analysing pulsatile retinal capillary flow and arteriolar structural parameters measured noninvasively in hypertensive patients. Journal of Hypertension, 2014, 32, 2246-2252.	0.5	11
234	Achievement of individualized treatment targets in patients with comorbid type-2 diabetes and hypertension: 6Âmonths results of the DIALOGUE registry. BMC Endocrine Disorders, 2015, 15, 23.	2.2	11

#	Article	IF	CITATIONS
235	Circadian rhythm and day to day variability of serum potassium concentration: a pilot study. Journal of Nephrology, 2015, 28, 165-172.	2.0	11
236	Early Signs of Endâ€Organ Damage in Retinal Arterioles in Patients with Type 2 Diabetes Compared to Hypertensive Patients. Microcirculation, 2016, 23, 447-455.	1.8	11
237	Mid-Term Vascular Safety of Renal Denervation Assessed by Follow-up MR Imaging. CardioVascular and Interventional Radiology, 2016, 39, 426-432.	2.0	11
238	Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 364-371.	3.0	11
239	Changes in Stroke Volume After Renal Denervation. Hypertension, 2020, 75, 707-713.	2.7	11
240	Improved blood pressure control via a novel chronic disease management model of care in subâ€Saharan Africa: Realâ€world program implementation results. Journal of Clinical Hypertension, 2021, 23, 785-792.	2.0	11
241	Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk. Cardiovascular Diabetology, 2022, 21, 12.	6.8	11
242	Renal hemodynamic response to stress is influenced by ACE-inhibitors. Clinical Nephrology, 1994, 42, 381-8.	0.7	11
243	Effects of angiotensin converting enzyme inhibitor on renal haemodynamics during mental stress. Journal of Hypertension, 1996, 14, 1201-1207.	0.5	10
244	Not all left ventricular hypertrophy is created equal. Nephrology Dialysis Transplantation, 1999, 14, 2803-2805.	0.7	10
245	Effects of angiotensin II type 1-receptor blockade on retinal endothelial function. Journal of Hypertension, 2008, 26, 516-522.	0.5	10
246	Central arteriovenous anastomosis to treat resistant hypertension. Current Opinion in Nephrology and Hypertension, 2018, 27, 8-15.	2.0	10
247	Effects of the nitric oxide synthase inhibitor ronopterin (VAS203) on renal function in healthy volunteers. British Journal of Clinical Pharmacology, 2019, 85, 900-907.	2.4	10
248	Retinal neurodegeneration in patients with end-stage renal disease assessed by spectral-domain optical coherence tomography. Scientific Reports, 2020, 10, 5255.	3.3	10
249	Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine. Cardiovascular Diabetology, 2021, 20, 178.	6.8	10
250	Twenty-Four-Hour Pulsatile Hemodynamics Predict Brachial Blood Pressure Response to Renal Denervation in the SPYRAL HTN-OFF MED Trial. Hypertension, 2022, 79, 1506-1514.	2.7	10
251	Is l-arginine infusion an adequate tool to assess endothelium-dependent vasodilation of the human renal vasculature?. Clinical Science, 2000, 99, 293.	4.3	9
252	The potential role of prorenin in diabetic nephropathy. Journal of Hypertension, 2007, 25, 1323-1326.	0.5	9

#	Article	IF	CITATIONS
253	Cerebral Microangiopathy in Treatmentâ€Resistant Hypertension. Journal of Clinical Hypertension, 2011, 13, 582-587.	2.0	9
254	Patients With Newly Diagnosed Hypertension Treated With the Renin Angiotensin Receptor Blocker Azilsartan Medoxomil vs Angiotensinâ€Converting Enzyme Inhibitors: The Prospective <scp>EARLY</scp> Registry. Journal of Clinical Hypertension, 2015, 17, 947-953.	2.0	9
255	Aldosterone Antagonists and Renal Denervation. Hypertension, 2015, 65, 280-282.	2.7	9
256	Oxidized LDL, statin use, morbidity, and mortality in patients receiving maintenance hemodialysis. Free Radical Research, 2017, 51, 14-23.	3.3	9
257	Visit-to-visit blood pressure variability and renal outcomes: results from ONTARGET and TRANSCEND trials. Journal of Hypertension, 2020, 38, 2050-2058.	0.5	9
258	Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk. Journal of Hypertension, 2021, 39, 766-774.	0.5	9
259	Renal denervation in patients with chronic kidney disease: current evidence and future perspectives. Nephrology Dialysis Transplantation, 2023, 38, 1089-1096.	0.7	9
260	Aliskiren, a novel orally effective renin inhibitor, provides antihypertensive efficacy and placebo-like tolerability similar to an at1-receptor blocker in hypertensive patients. American Journal of Hypertension, 2004, 17, S108.	2.0	8
261	Olmesartan Improves Pulse Wave Velocity and Lowers Central Systolic Blood Pressure and Ambulatory Blood Pressure in Patients With Metabolic Syndrome. Journal of Clinical Hypertension, 2015, 17, 98-104.	2.0	8
262	The Effect of Resting Heart Rate on the New Onset of Microalbuminuria in Patients With Type 2 Diabetes. Medicine (United States), 2016, 95, e3122.	1.0	8
263	The effect of renal denervation in moderate treatment-resistant hypertension with confirmed medication adherence. Journal of Hypertension, 2016, 34, 2475-2479.	0.5	8
264	Scientific Data and Transparency of Conflict of Interest Are Important, Not Biased Editorial Without Facts. JACC: Cardiovascular Interventions, 2016, 9, 2263.	2.9	8
265	Aortic stiffness is not only associated with structural but also functional parameters of retinal microcirculation. Microvascular Research, 2020, 129, 103974.	2.5	8
266	Long-Term Results up to 12 Months After Catheter-Based Alcohol-Mediated Renal Denervation for Treatment of Resistant Hypertension. Circulation: Cardiovascular Interventions, 2021, 14, e010075.	3.9	8
267	Angiotensin Blockade to Reduce Microvascular Damage in Diabetes Mellitus. Deutsches Ärzteblatt International, 2009, 106, 556-62.	0.9	7
268	Wall-to-lumen ratio of retinal arterioles. Journal of Hypertension, 2012, 30, 1108-1110.	0.5	7
269	EARLY Treatment with azilsartan compared to ACE-inhibitors in anti-hypertensive therapy – rationale and design of the EARLY hypertension registry. BMC Cardiovascular Disorders, 2013, 13, 46.	1.7	7
270	Does Renal Artery Supply Indicate Treatment Success of Renal Denervation?. CardioVascular and Interventional Radiology, 2013, 36, 987-991.	2.0	7

#	Article	IF	CITATIONS
271	Catheter-Based Renal Nerve Ablation and Centrally Generated Sympathetic Activity in Difficult-to-Control Hypertensive Patients: Prospective Case Series. Hypertension, 2013, 61, e17.	2.7	7
272	Optimizing blood pressure control in hypertension: The need to use ABPM. Blood Pressure, 2013, 22, 65-72.	1.5	7
273	Invasive Treatment of Resistant Hypertension: Present and Future. Current Hypertension Reports, 2014, 16, 488.	3.5	7
274	Renal Denervation for Resistant Hypertension: Past, Present, and Future. Current Hypertension Reports, 2015, 17, 65.	3.5	7
275	Non-invasive Renal Denervation: Update on External Ultrasound Approaches. Current Hypertension Reports, 2016, 18, 48.	3.5	7
276	Left Ventricular Structure in Patients With Mild-to-Moderate CKD—a Magnetic Resonance Imaging Study. Kidney International Reports, 2019, 4, 267-274.	0.8	7
277	3D-Visualization of Neurovascular Compression at the Ventrolateral Medulla in Patients with Arterial Hypertension. Clinical Neuroradiology, 2020, 31, 335-345.	1.9	7
278	Rosuvastatin does not affect intrarenal hemodynamics in patients with hypercholesterolemia. Journal of Nephrology, 2009, 22, 675-81.	2.0	7
279	Change in Augmentation Index during NOS Inhibition, an Index of Basal NO Production, Is an Independent Determinant of Large-Artery Function. Kidney and Blood Pressure Research, 2010, 33, 343-351.	2.0	6
280	Lumen narrowing and increased wall to lumen ratio of retinal microcirculation are valuable biomarkers of hypertension-mediated cardiac damage. Blood Pressure, 2020, 29, 70-79.	1.5	6
281	Renal and intraglomerular haemodynamics in chronic heart failure with preserved and reduced ejection fraction. ESC Heart Failure, 2021, 8, 1562-1570.	3.1	6
282	Dependency of flowâ€mediated vasodilatation from basal nitric oxide activity. Clinical Physiology and Functional Imaging, 2021, 41, 310-316.	1.2	6
283	Plasma renin and aldosterone concentrations related to endovascular ultrasound renal denervation in the RADIANCE-HTN SOLO trial. Journal of Hypertension, 2022, 40, 221-228.	0.5	6
284	Catheter-based Renal Sympathetic Denervation – Long-term Symplicityâ,,¢ Renal Denervation Clinical Evidence, New Data and Future Perspectives. Interventional Cardiology Review, 2013, 8, 118.	1.6	6
285	Ruling out secondary causes of hypertension. EuroIntervention, 2013, 9, R21-R28.	3.2	6
286	The influence of aircraft noise exposure on the systemic and renal haemodynamics. European Journal of Preventive Cardiology, 2022, 29, 116-124.	1.8	6
287	Editorial comment: Renal denervation. Hypertension Research, 2022, 45, 241-243.	2.7	6
288	Risks Versus Benefits of Withdrawing Antihypertensive Therapy. Drug Safety, 1992, 7, 395-403.	3.2	5

#	Article	IF	CITATIONS
289	Pharmacokinetics of Valsartan in Hypertensive Patients on Long-Term Haemodialysis. Clinical Drug Investigation, 2001, 21, 59-66.	2.2	5
290	Achievement of recommended glucose and blood pressure targets in patients with type 2 diabetes and hypertension in clinical practice study rationale and protocol of DIALOGUE. Cardiovascular Diabetology, 2012, 11, 148.	6.8	5
291	Prevention of electrocardiographic left ventricular remodeling by the angiotensin receptor blocker olmesartan in patients with type 2 diabetes. Journal of Hypertension, 2014, 32, 2267-2276.	0.5	5
292	The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry. Trials, 2015, 16, 581.	1.6	5
293	Percutaneous Creation of a Central Iliac Arteriovenous Anastomosis for the Treatment of Arterial Hypertension. Current Hypertension Reports, 2018, 20, 18.	3.5	5
294	Secretory Capacity of Pancreatic Beta-Cells Is Enhanced 6 Months After Renal Denervation in Hypertensive Patients. Journal of the American College of Cardiology, 2018, 72, 3372-3374.	2.8	5
295	Reference values of retinal microcirculation parameters derived from a population random sample. Microvascular Research, 2021, 134, 104117.	2.5	5
296	Novel approaches to management of hypertension. Current Opinion in Nephrology and Hypertension, 2021, 30, 54-62.	2.0	5
297	Cardiovascular outcomes in patients at high cardiovascular risk with previous myocardial infarction or stroke. Journal of Hypertension, 2021, 39, 1602-1610.	0.5	5
298	Association of Noise Annoyance with Measured Renal Hemodynamic Changes. Kidney and Blood Pressure Research, 2021, 46, 323-330.	2.0	5
299	Tissue sodium content correlates with hypertrophic vascular remodeling in type 2 diabetes. Journal of Diabetes and Its Complications, 2021, 35, 108055.	2.3	5
300	Tissue sodium content in hypertension and related organ damage. Journal of Hypertension, 2020, 38, 2363-2368.	0.5	5
301	When is discontinuation of antihypertensive therapy indicated?. Cardiovascular Drugs and Therapy, 1990, 4, 1487-1494.	2.6	4
302	Renal and Systemic Hemodynamics in Black and White Hypertensive Patients. American Journal of Hypertension, 1997, 10, 971-978.	2.0	4
303	Comment on ESH position paper. Journal of Hypertension, 2012, 30, 2443.	0.5	4
304	Haemoglobin and vascular function in the human retinal vascular bed. Journal of Hypertension, 2013, 31, 775-781.	0.5	4
305	Retinal microperfusion after renal denervation in treatment-resistant hypertensive patients. Clinical Research in Cardiology, 2015, 104, 782-789.	3.3	4
306	Expertise: No Longer a Sine Qua Non for Guideline Authors?. Hypertension, 2017, 70, 235-237.	2.7	4

#	Article	IF	CITATIONS
307	How to measure retinal microperfusion in patients with arterial hypertension. Blood Pressure, 2021, 30, 4-19.	1.5	4
308	Identifying Isolated Systolic Hypertension From Upper-Arm Cuff Blood Pressure Compared With Invasive Measurements. Hypertension, 2021, 77, 632-639.	2.7	4
309	Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers. Cardiovascular Diabetology, 2022, 21, 4.	6.8	4
310	Hypertensive heart diseasesignificance of left ventricular hypertrophy. Journal of Cardiovascular Pharmacology, 1992, 20 Suppl 6, S50-5.	1.9	4
311	Significance of initial blood pressure and comorbidity for the efficacy of a fixed combination of an angiotensin receptor blocker and hydrochlorothiazide in clinical practice. Vascular Health and Risk Management, 2009, 5, 991.	2.3	3
312	Diagnosis and treatment of resistant hypertension. Blood Pressure, 2014, 23, 193-199.	1.5	3
313	Retinal arterial remodeling in patients with pheochromocytoma or paraganglioma and its reversibility following surgical treatment. Journal of Hypertension, 2020, 38, 1551-1558.	0.5	3
314	Detection of Changes in Renal Blood Flow Using Arterial Spin Labeling MRI. American Journal of Nephrology, 2021, 52, 69-75.	3.1	3
315	Is l-arginine infusion an adequate tool to assess endothelium-dependent vasodilation of the human renal vasculature?. Clinical Science, 2000, 99, 293-302.	4.3	3
316	Current status of renal denervation in resistant hypertension. Journal of the American Society of Hypertension, 2012, 6, 414-416.	2.3	2
317	1-Year outcomes of hypertension management in 13,000 outpatients under practice conditions: Prospective 3A registry. International Journal of Cardiology, 2014, 176, 589-594.	1.7	2
318	Managing Treatment-Resistant Patients. High Blood Pressure and Cardiovascular Prevention, 2015, 22, 11-13.	2.2	2
319	Retinal Circulation in Arterial Disease. , 2015, , 397-414.		2
320	Two‥ear Outcomes of Patients Treated With Aliskiren Under Clinical Practice Conditions: Nonâ€Interventional Prospective Study. Journal of Clinical Hypertension, 2016, 18, 647-654.	2.0	2
321	Benefits and Risks of Aliskiren Treatment in Patients With Type 2 Diabetes: Analyses of the 3A Registry. Journal of Clinical Hypertension, 2016, 18, 1045-1053.	2.0	2
322	Increased Aldosterone Release During Head-Up Tilt in Early Primary Hypertension. American Journal of Hypertension, 2017, 30, 484-489.	2.0	2
323	Neurogenic substance P—influences on action potential production in afferent neurons of the kidney?. Pflugers Archiv European Journal of Physiology, 2021, 473, 633-646.	2.8	2
324	Relationship Between Ubiquitin-Specific Peptidase 18 and Hypertension in Polish Adult Male Subjects: A Cross-Sectional Pilot Study. Medical Science Monitor, 2020, 26, e921919.	1.1	2

#	Article	IF	CITATIONS
325	Angiotensin II-Type 2 Receptor: Emerging Target for Cardiovascular Protection. American Journal of Hypertension, 2010, 23, 220-220.	2.0	1
326	Application of a central iliac arteriovenous coupler device in severe treatment-resistant hypertension. Journal of Hypertension, 2018, 36, 2471-2477.	0.5	1
327	Copeptin Levels in Patients With Treatment-Resistant Hypertension Before and 6 Months After Renal Denervation. American Journal of Hypertension, 2019, 33, 182-189.	2.0	1
328	Hypertrophic remodelling of retinal arterioles in patients with congestive heart failure. ESC Heart Failure, 2021, 8, 1892-1900.	3.1	1
329	Response to: Cavagna et al The importance of considering cultural and environmental elements in an interventional model of care to fight hypertension in Africa. Journal of Clinical Hypertension, 2021, 23, 1271-1272.	2.0	1
330	Reversal of left ventricular hypertrophy: a desirable therapeutic goal?. Journal of Cardiovascular Pharmacology, 1990, 16 Suppl 6, S16-22.	1.9	1
331	Angiotensin II stimulates left ventricular hypertrophy in hypertensive patients independently of blood pressure. American Journal of Hypertension, 1999, 12, 418-422.	2.0	Ο
332	Hypertension and Diabetes. Diabetes Care, 2009, 32, S294-S297.	8.6	0
333	Blood pressure and retinal small arteries. Journal of Hypertension, 2013, 31, 1946-1947.	0.5	Ο
334	Damage of Retinal Arterioles in Hypertension. , 2015, , 127-142.		0
335	The impact of age on the benefits and risks of aliskiren treatment: analyses of the 3A registry. Journal of Human Hypertension, 2015, 29, 316-323.	2.2	Ο
336	4325How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus?. European Heart Journal, 2018, 39, .	2.2	0
337	Assessment of Target Organ Damage. , 2018, , 189-199.		0
338	New data, new studies, new hopes for renal denervation in patients with uncontrolled hypertension. International Journal of Cardiology: Hypertension, 2019, 3, 100022.	2.2	0
339	Neurovascular Compression in Arterial Hypertension: Correlation of Clinical Data to 3D-Visualizations of MRI-Findings. Open Neuroimaging Journal, 2021, 14, 16-27.	0.2	Ο
340	The Optic Fundus and Retinal Circulation: New Technology for an Old Examination. , 2012, , 157-168.		0
341	Alternative Methods for Renal Denervation. Updates in Hypertension and Cardiovascular Protection, 2016, , 321-337.	0.1	0
342	Assessment of Retinal Arteriolar Morphology by SLDF. Updates in Hypertension and Cardiovascular Protection, 2020, , 27-41.	0.1	0

#	Article	IF	CITATIONS
343	The authors reply. Kidney International, 2022, 101, 830-832.	5.2	0
344	Nephroprotection by antihypertensive agents. Journal of Cardiovascular Pharmacology, 1994, 24 Suppl 2, S55-64.	1.9	0
345	Obese hypertensive patients are less effectively treated than lean hypertensives. Journal of Hypertension Supplement: Official Journal of the International Society of Hypertension, 1993, 11, S348-9.	0.1	0